IN THE PRESS

5th Annual CERSI Innovations in Regulatory Science Summit | UCSF-Stanford CERSI | 01/31/2024

Pharma Patents and the American Way of Innovation | WSJ | 12/19/2023

Former White House Economic Adviser Discusses Covid Policies at HUEA Event | Harvard Undergraduate Economics Association | 12/01/2023

Are PBMs Good For Competition? A Cost-Benefit Analysis of the Effects of Regulating Pharmacy Benefit Managers | Our Curious Amalgam | 10/2/23

The IRA’s Impact on Cancer Patients Is Worse than Predicted | RealClear Health | 10/24/2023

We Need More ‘Warp Speed’ Operations | WSJ | 10/6/23

The Problems with Drug Price Controls | The National Review Capital Matters | 9/27/23

Gilead-backed study warns IRA price negotiations could hit R&D harder than expected | Fierce Biotech | 09/06/2023

The SMART Prices Act Deserves a Failing Grade | RealClearHealth | 07/31/2023

A new Alzheimer’s drug wins FDA approval, but why it may still be out of reach. | USA Today | 07/07/2023

The SMART Prices Act is anything but smart | The Hill | 06/29/23

Three reforms that will lower Medicare costs and improve care | The Hill | 06/25/23

Casey Mulligan on Vaccines, the Pandemic, and the FDA | The Library of Economics and Liberty | 05/22/23

Tomas Philipson: By avoiding funding Alzheimer’s research, the government is cutting seniors’ life spans | The Chicago Tribune | 05/18/2023

No, Lockdown States Did Not Do Better | National Review | 04/19/2023

Legislators should monitor mission creep at CMS’s flush price control center | The Hill | 04/12/23

The Deadly Side Effects of Drug Price Controls | WSJ | 4/5/23

Profitable Science Empowers Patients | Washington Examiner | 3/14/23

EDITORIAL: The side effects of drug price controls | The Review Journal | 02/17/23

How Deadly Were the Covid Lockdowns? | WSJ | 01/11/23

Tomas Philipson: Health care policy is ‘most damaging’ issue not discussed by economists | Fox News | 11/21/22

The Inflation Reduction Act Comes for Medicare | WSJ | 11/21/22

In Defense of Pharmacy Benefit Managers | WSJ | 07/11/22

The Economics of Obesity | WSJ | 06/28/22

President Biden’s unintended war on cancer patients | The Hill | 06/28/22

Lockdown Damage | City Journal | 06/13/22

The Value of Employer-Sponsored Health Insurance: A Summary | American Action Forum | 04/12/22

A Final Report Card on the States’ Response to COVID-19 | April 2022

NBER Spotlight – Substance Abuse and the COVID-19 Pandemic | NBER | 2/7/23

An Economic Evaluation of Covid Lockdowns | WSJ | 1/19/22

The Backward Art of Slowing the Spread? Congregation Efficiencies During Covid 19 | The Hoover Institution – Stanford University | 01/19/22

House Committee on Energy and Commerce Hearing – The Future of Biomedicine: Translating Biomedical Research into Personalized Health Care | 12/8/21

Biden’s Price Controls Will Make Good Health More Expensive | WSJ | 09/15/21

Government Failure Gave the World Covid | WSJ | 8/9/21

How Chicago Economics is Helping End a Pandemic: Enabling Choice and Competition in Healthcare | 2/5/21

Is the COVID cure worse than the disease? | The Hill | 02/06/21

Deaths of Despair and the Incidence of Excess Mortality in 2020 | VOX, CEPR Policy Portal (voxeu.org) | 1/28/21

Deaths of Despair and the Incidence of Excess Mortality in 2020 | CEPR | 01/28/21

Should Double Charging Patients for Medication be Legal? | Newsweek | 01/14/21

How Government Subsidized the Opioid Crisis | WSJ | 1/3/21

How Government Subsidized the Opioid Crisis | WSJ | 01/03/21

Operation Warp Speed: What a Deal! | Newsweek.com | 7/28/20

Operation Warp Speed: What a Deal! | Newsweek | 07/28/20

Corona Economics | Casey B. Mulligan | Friedberg Economics Institute | 05/25/20

Some Basic Economics of COVID-19 Policy | Chicago Booth | 04/27/20

Scroll to Top